MedTrace Logo

The Use of DPP-4 Inhibitors in Short Bowel Syndrome

NCT02653131 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-04-15

No results posted yet for this study

Summary

The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Conditions

  • Short Bowel Syndrome

Interventions

DRUG

Dipeptidyl peptidase-4 inhibitor

Sponsors & Collaborators

  • Stanley Dudrick's Memorial Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02653131 on ClinicalTrials.gov